Evidence map›Paper›PMID 30463616›Full record

ArticleBMC psychiatry2018

The Italian autism network (ITAN): a resource for molecular genetics and biomarker investigations.

Pierandrea Muglia, Michele Filosi, Lucio Da Ros, Tony Kam-Thong, Franco Nardocci, Elisabetta Trabetti, Emiliangelo Ratti, Paolo Rizzini, Alessandro Zuddas, Bernardo Dalla Bernardina and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Pierandrea MugliaUCB Pharma, Bruxelles, Belgium. pierandrea.muglia@ucb.com.
Michele FilosiCentre for Integrative Biology, University of Trento, Trento, Italy.
Lucio Da RosFondazione Smith Kline, Verona, Italy.
Tony Kam-ThongRoche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Grenzacherstrasse 124, Basel, Switzerland.
Franco NardocciNeuropsichiatria infantile, Modena, Italy.
Elisabetta TrabettiDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
Emiliangelo RattiCentral Nervous System (CNS) Therapeutic Area Unit, Takeda, Boston, USA.
Paolo RizziniFondazione Smith Kline, Verona, Italy.
Alessandro ZuddasChild and Adolescent Psychiatry Unit, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
Bernardo Dalla BernardinaServizio di Neuropsichiatria Infantile Azienda Ospedaliera Istituti Ospitalieri di Verona Policlinico G.B. Rossi, Verona, Italy.
Enrico DomeniciCentre for Integrative Biology, University of Trento, Trento, Italy. enrico.domenici@unitn.it.ORCID 0000-0001-7436-6919
Italian Autism Network
University of Trento · ITRoche (Switzerland) · CHUniversity of Cagliari · ITUniversity of Verona · ITTakeda (United States) · USUCB Pharma (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA substantial genetic component accounts for Autism Spectrum Disorders (ASD) aetiology, with some rare and common genetic risk factors recently identified. Large collections of DNAs from thoroughly characterized ASD families are an essential step to confirm genetic risk factors, identify new variants and investigate genotype-phenotype correlations. The Italian Autism Network aimed at constituting a clinical database and a biorepository of samples derived from ASD subjects and first-degree relatives extensively and consistently characterized by child psychiatry centers in Italy.

methodsThe study was approved by the ethical committee of the University of Verona, the coordinating site, and by the local ethical committees of each recruiting site. Certified staff was specifically trained at each site for the overall study conduct, for clinical protocol administration and handling of biological material. A centralized database was developed to collect clinical assessment and medical records from each recruiting site. Children were eligible for recruitment based on the following inclusion criteria: age 4-18 years, at least one parent or legal guardian giving voluntary written consent, meeting DSM-IV criteria for Autistic Disorder or Asperger's Disorder or Pervasive Developmental Disorder NOS. Affected individuals were assessed by full psychiatric, neurological and physical examination, evaluation with ADI-R and ADOS scales, cognitive assessment with Wechsler Intelligence Scale for Children or Preschool and Primary, Leiter International Performance Scale or Griffiths Mental Developmental Scale. Additional evaluations included language assessment, the Krug Asperger's Disorder Index, and instrumental examination such as EEG and structural MRI. DNA, RNA and plasma were collected from eligible individuals and relatives. A central laboratory was established to host the biorepository, perform DNA and RNA extraction and lymphocytes immortalisation. DISCUSSION: The study has led to an extensive collection of biological samples associated with standardised clinical assessments from a network of expert clinicians and psychologists. Eighteen sites have received ADI/ADOS training, thirteen of which have been actively recruiting. The clinical database currently includes information on 812 individuals from 249 families, and the biorepository has samples for 98% of the subjects. This effort has generated a highly valuable resource for conducting clinical and genetic research of ASD, amenable to further expansion.

Indexed as

Asperger SyndromeAutism Spectrum DisorderChild Development Disorders, PervasiveAdolescentBiological Specimen BanksBiomarkersChildChild, PreschoolDatabases as TopicFemaleHealth ResourcesHumansItalyMaleMedical RecordsBiomarkersAutism Spectrum disordersBiomarkersBiorepositoryGenetics

Identifiers

PMID30463616
PMCPMC6247619
OpenAlexW2951133175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.